Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Italy / NCT05276388
Active, not recruiting Observational

Establishment of a Biological Biobank of Subjects Vaccinated Against SARS-CoV-2 Infection (COVID-19)

NCT05276388 · tracked via the Priya Life Science Italy tracker
Sponsor
IRCCS San Raffaele
Phase
Observational
Started
2021-01-01
Last updated
2025-05-30

Condition(s) studied

Coronavirus Infections

Investigational drug(s) / intervention(s)

biological bank

biological bank: biological bank of subjects vaccinated against SARS-CoV-2 infection

Study summary

Establishment of a biological bank of subjects vaccinated against SARS-Cov-2 infection (COVID-BioVac)

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: * Age ≥18 years * Who have vaccinated for SARS-CoV-2 with Pfizer-BioNTech vaccine or others * Signing of informed consent from January to March 2021 Exclusion Criteria: * none

Primary outcome measure(s)

  • COVID-19 vaccines response — from Day 1 of first vaccination up to 1 years after the last vaccination
    Create a Biobank to evaluate the immunogenicity of COVID-19 vaccines in terms of antibody titers

Trial sites (1)

FacilityCityRegionStatus
IRCCS Ospedale San Raffaele Milan Milano

More IRCCS San Raffaele trials in Italy

Patient Reported Outcome Measurements (PROMs) Impact on Clinical Outcome in firsT Line settIng Non- Small-Cell Lung Cancer (NSCLC) According to Chemo- Immunotherapy reGimen Recruiting
Improving Safety and Accuracy of Stereotactic Brain Biopsies in Primary Central Nervous System Lymphoma. Recruiting
Medically Assisted Fertilization Techniques in Systemic Immunoreumatologic Diseases Recruiting
Development of Novel Imaging and Molecular Biomarkers of Fibrosis in Patient With Ulcerative Colitis Recruiting
Next-Generation Endometriosis Diagnostics Through Comprehensive Multi-Dimensional Analysis Recruiting

Other trials for the same condition

COVID-19 Patients Characterization, Biobank, Treatment Response and Outcome Predictor Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05276388 on ClinicalTrials.gov ↗ ← All trials in Italy